Stay updated with breaking news from Maximal Usage Systemic Exposure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S.
This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.
Roflumilast is the first topical agent indicated to treat psoriasis in sensitive intertriginous areas of the skin.
The FDA has approved Zoryve (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children ages 6 to 11 years.
This marks an expanded indication for the drug, which was first approved for the same indication in July 2022 for individuals aged 12 and older.